
Joshua K. Sabari, MD, highlights pharmacists’ roles in coordinating access, financial assistance, and early adverse effect management for patients starting zongertinib (Hernexeos).
Joshua K. Sabari, MD, highlights pharmacists’ roles in coordinating access, financial assistance, and early adverse effect management for patients starting zongertinib (Hernexeos).
Joshua K. Sabari, MD, explains zongertinib’s (Hernexeos) favorable safety profile and quality-of-life benefits over intravenous antibody-drug conjugates in patients with HER2-mutated non-small cell lung cancer (NSCLC).
Joshua K. Sabari, MD, discusses how zongertinib’s inclusion in the National Comprehensive Care Network (NCCN) guidelines represents a game-changing second-line treatment for HER2-mutant non-small cell lung cancer (NSCLC).
Zongertinib shows promising efficacy and safety for HER2-mutant NSCLC, with a 71% response rate and low toxicity, paving the way for future treatments.
Philip Kuball, MD, neurology resident at NYU Langone Health, highlights the integral role of pharmacists in monitoring patient eligibility, managing dosing schedules, and ensuring safe medication interactions for lecanemab treatment in Alzheimer disease.
Lauren B. Krupp, MD, FAAN, provides comprehensive guidance on treating pediatric multiple sclerosis, emphasizing early intervention, high-efficacy therapies, and holistic family support.
Kara Melmed, MD, emphasizes the critical importance of rapid, team-based intervention for intracerebral hemorrhage (ICH) patients, with pharmacists playing a key role in blood pressure management.